NO20084913L - Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav - Google Patents

Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav

Info

Publication number
NO20084913L
NO20084913L NO20084913A NO20084913A NO20084913L NO 20084913 L NO20084913 L NO 20084913L NO 20084913 A NO20084913 A NO 20084913A NO 20084913 A NO20084913 A NO 20084913A NO 20084913 L NO20084913 L NO 20084913L
Authority
NO
Norway
Prior art keywords
composition containing
neoplastic agent
iron chelator
combination
triazolyl
Prior art date
Application number
NO20084913A
Other languages
English (en)
Norwegian (no)
Inventor
Hanspeter Nick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084913L publication Critical patent/NO20084913L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20084913A 2006-05-09 2008-11-21 Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav NO20084913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74678806P 2006-05-09 2006-05-09
PCT/EP2007/054456 WO2007128820A1 (en) 2006-05-09 2007-05-08 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof

Publications (1)

Publication Number Publication Date
NO20084913L true NO20084913L (no) 2009-02-05

Family

ID=38282831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084913A NO20084913L (no) 2006-05-09 2008-11-21 Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav

Country Status (17)

Country Link
US (2) US20090317489A1 (ko)
EP (2) EP2272511A1 (ko)
JP (1) JP2009536180A (ko)
KR (1) KR20090007635A (ko)
CN (1) CN101443002B (ko)
AU (1) AU2007247112B2 (ko)
BR (1) BRPI0711385A2 (ko)
CA (1) CA2649792A1 (ko)
IL (1) IL194819A0 (ko)
MA (1) MA31130B1 (ko)
MX (1) MX2008014292A (ko)
NO (1) NO20084913L (ko)
NZ (1) NZ572299A (ko)
RU (1) RU2469721C2 (ko)
TN (1) TNSN08447A1 (ko)
WO (1) WO2007128820A1 (ko)
ZA (1) ZA200808961B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009340A1 (en) * 2008-02-19 2011-01-13 Novartis Ag Combination of an iron chelator and an immunosuppressant and use thereof
US20130011411A1 (en) * 2010-01-06 2013-01-10 Pestell Richard G Methods and compositions for the diagnosis, prognosis, and treatment of cancer
US20140073645A1 (en) * 2011-03-21 2014-03-13 Vivolux Ab Treatment of Solid Tumours
WO2014046589A1 (en) 2012-09-21 2014-03-27 Vivolux Ab Means and method for treating solid tumours
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN110075120B (zh) * 2018-10-11 2022-03-11 广东众尔健生物科技有限公司 一种组合物及其在抗肿瘤药物中的应用
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2182943A1 (en) 1972-04-10 1973-12-14 Rustenburg Platinum Mines Ltd Cis-dihalo-bis(ethyleneimine) platinum (ii) derivs - anti-cancer agents
CH605550A5 (ko) 1972-06-08 1978-09-29 Research Corp
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4939168A (en) 1989-08-11 1990-07-03 Harbor Branch Oceanographics Institution, Inc. Discodermolide compounds, compositions containing same and methods of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (ko) 1992-04-03 1994-06-21 Ciba Geigy Ag
HU225646B1 (en) 1992-10-28 2007-05-29 Genentech Inc Hvegf receptors as vascular endothelial cell growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9315802D0 (en) 1993-07-30 1993-09-15 Roussel Lab Ltd Chemical compounds
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
US5618487A (en) 1995-02-21 1997-04-08 Hettinga; Siebolt Multi-clamp mold and method for clamping an injection mold assembly
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CZ295468B6 (cs) 1996-04-12 2005-08-17 Warner-Lambert Company Polycyklické sloučeniny
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CZ303422B6 (cs) 1996-11-18 2012-09-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TWI272273B (en) * 2002-07-16 2007-02-01 Sonus Pharma Inc Platinum compounds
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
CA2515424A1 (en) * 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
GEP20094664B (en) * 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition

Also Published As

Publication number Publication date
BRPI0711385A2 (pt) 2011-11-08
AU2007247112A1 (en) 2007-11-15
NZ572299A (en) 2010-07-30
IL194819A0 (en) 2009-08-03
MX2008014292A (es) 2008-11-18
EP2272511A1 (en) 2011-01-12
WO2007128820A1 (en) 2007-11-15
ZA200808961B (en) 2009-08-26
EP2026800A1 (en) 2009-02-25
RU2469721C2 (ru) 2012-12-20
JP2009536180A (ja) 2009-10-08
KR20090007635A (ko) 2009-01-19
MA31130B1 (fr) 2010-02-01
US20110159114A1 (en) 2011-06-30
RU2008148167A (ru) 2010-06-20
US20090317489A1 (en) 2009-12-24
TNSN08447A1 (en) 2010-04-14
CN101443002B (zh) 2012-03-21
CN101443002A (zh) 2009-05-27
CA2649792A1 (en) 2007-11-15
AU2007247112B2 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
NO20084913L (no) Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav
MX2009012000A (es) Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
NO20080150L (no) Inhibitorer av AKT-aktivitet
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
NO20082496L (no) Pyrazinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20090628L (no) Pyridizinon derivativater
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
TN2009000487A1 (en) Triazol compounds for treating biofilm formation
UA107324C2 (uk) Похідні 1,2,3-триазолу для застосування як інгібіторів стеароїл-coa десатурази
NO20091626L (no) MGLUR5-modulatorer
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
MXPA06012566A (es) Tratamiento de enfermedades infecciosas.
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
ATE330928T1 (de) Substituierte chalkone als arzneimitteln
WO2007075650A3 (en) Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
TW200716618A (en) Chemical compounds
NO20090193L (no) Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser
MX2009012375A (es) Uso de quelante del hierro para el tratamiento del infarto de miocardio.
NO20076075L (no) 4-anilino-3-kinolinkarbonitriler for behandling av cancer
UA88766C2 (ru) Производные хинолина для лечения латентного туберкулеза
NO20032411D0 (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application